No Data
No Data
Express News | ApicHope Pharmaceutical: AR882 has not yet been launched for sale and has not generated any sales revenue.
A-shares are moving, Innovative Drugs Concept stocks are strong, ApicHope Pharmaceutical is up 20cm, hitting a historical high.
Globe News, April 14 | A-shares in the Innovative Drugs concept sector performed strongly, with ApicHope Pharmaceutical and Youcare Pharmaceutical Group both hitting the 20% daily limit. ApicHope's stock price reached a historical high, recording two consecutive days of the daily limit. Kexing Biopharm and Fujian Cosunter Pharmaceutical rose over 14%, while Yantai Dongcheng Biochemicals, Beijing Aosaikang Pharmaceutical, Staidson, and Yahui Pharmaceutical all gained over 7.5%. On the news front, a report from Industrial Securities indicated that there are continuous catalysts in the Innovative Drugs field, including overseas licensing, domestic policies, and clinical data progress. Compared to last year, it is expected that there will be more significant data for domestic innovative drugs this year, which is likely to bring positive catalysts to the Innovative Drugs sector. China Securities Co.,Ltd. expressed a Bullish outlook that is currently unaffected.
ApicHope Pharmaceutical (300723): Children's medicine and chronic disease medicine are flourishing in multiple areas, with a new gout drug contributing to the additional growth.
Characteristic children's pharmaceuticals and chronic disease drugs dominate, and the Innovative Drugs for gout are expected to contribute to growth. The company was established in 2002 and mainly focuses on the fields of children's pharmaceuticals and chronic disease drugs, and is now an innovative Biomedical enterprise that integrates pharmaceutical research and development, production, and sales.
ApicHope Pharmaceutical (300723): A turnaround in difficulties, a major gout product is emerging.
The main business is expected to bottom out and rebound, and there is a significant expectation gap for the innovative drug AR882 for gout. Since 2022, the company's performance has been under pressure due to disruptions from industry collective procurement, changes in the market environment, and increased losses from overseas Innovative Drugs subsidiaries, along with policies.
ApicHope Pharmaceutical (300723): Innovative research and development focuses on the gout field and is expected to come into a harvest period.
ApicHope Pharmaceutical: Focused on pediatric drugs and chronic disease medications, with research and development driving the continuous enrichment of the product matrix. ApicHope Pharmaceutical is an innovative Biomedical company focused on pediatric and chronic disease medication fields. The company is committed to creating an innovative R&D platform for pediatric formulations and has established a chronic disease innovation.
Express News | The concept of Innovative Drugs has fluctuated and surged, with Haisco Pharmaceutical Group hitting a limit-up and setting a historic high.